CO6251248A2 - Compuestos de tiazolopiridina como moduladores de sirtuina - Google Patents

Compuestos de tiazolopiridina como moduladores de sirtuina

Info

Publication number
CO6251248A2
CO6251248A2 CO10001887A CO10001887A CO6251248A2 CO 6251248 A2 CO6251248 A2 CO 6251248A2 CO 10001887 A CO10001887 A CO 10001887A CO 10001887 A CO10001887 A CO 10001887A CO 6251248 A2 CO6251248 A2 CO 6251248A2
Authority
CO
Colombia
Prior art keywords
compound
phenyl
pyridyl
optionally substituted
heterocycle
Prior art date
Application number
CO10001887A
Other languages
English (en)
Inventor
Jean Bemis
Jeremy Disch
Pui Yee Ng
Christopher Oalmann
Robert Perni
Chi B Vu
Original Assignee
Sirtris Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals filed Critical Sirtris Pharmaceuticals
Publication of CO6251248A2 publication Critical patent/CO6251248A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Se reivindica compuesto representado por la fórmula estructura (II):o una sal de éste, en donde: dos de X1 a X4 se seleccionan de -CR*- y -N-; los otros dos de X1 a X4 son -CR*-;R* es independientemente seleccionado en cada presencia de -H, alquilo inferior o halógeno; R1 es un grupo de solubilización; y R2 se selecciona de fenilo opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados de -CN, -F, -CI y -CF3, y cuando cada uno de X1 a X4 es CR*-, R2 se selecciona adicionalmente de un heterociclo de 5 a 6 miembros que contiene un heteroátomo N y, opcionalmente, un segundo heteroátomo seleccionado de N, O o S, en donde dicho heterociclo está opcionalmente sustituido con metilo. 2.- El compuesto de la Reivindicación 1 en donde: X1 a X4 es CR*-; y R2 se selecciona de fenilo, fluorofenilo, difluorofenilo, clorofenilo, metiltiazolilo, pirimidinilo, piridilo y pirazolilo. 3.- El compuesto de la Reivindicación 2, en donde R2 se selecciona de fenilo, fluorofenilo, difluorofenilo, clorofenilo, 2-metiltiazol-4-ilo, piridilo y pirazol-1-ilo. 4.- El compuesto de la Reivindicación 3, donde R2, es fenilo o piridilo. 5.- El compuesto de la Reivindicación 1, en donde uno de X1 a X4 son -N-. 6.- El compuesto de la Reivindicación 1, en donde uno de X1 a X4 son -N-. 7.- El compuesto de la Reivindicación 5, en donde X1 es N. 8.- El compuesto de la Reivindicación 6, en donde X1 a X2 son -N-. 9.- El compuesto de la Reivindicación 6, en donde X1 y X4 son -N-. 10.- El compuesto de cualquiera de las Reivindicaciones 1 a 9, en donde: R1 es -CH2-R3; y R3 es un heterociclo que contiene nitrógeno opcionalmente sustituido con uno o más sustituyentes seleccionados de alquilo C1-C4, amino, halógeno, metoxi y metoxi-alquilo C1-C4.
CO10001887A 2007-06-20 2010-01-08 Compuestos de tiazolopiridina como moduladores de sirtuina CO6251248A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93663607P 2007-06-20 2007-06-20

Publications (1)

Publication Number Publication Date
CO6251248A2 true CO6251248A2 (es) 2011-02-21

Family

ID=39798234

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10001887A CO6251248A2 (es) 2007-06-20 2010-01-08 Compuestos de tiazolopiridina como moduladores de sirtuina

Country Status (23)

Country Link
US (2) US7893086B2 (es)
EP (1) EP2170905A2 (es)
JP (1) JP5498940B2 (es)
KR (1) KR20100051048A (es)
CN (2) CN101801981A (es)
AR (1) AR067107A1 (es)
AU (1) AU2008266749C1 (es)
BR (1) BRPI0813651A2 (es)
CA (1) CA2691733A1 (es)
CL (1) CL2008001822A1 (es)
CO (1) CO6251248A2 (es)
CR (1) CR11232A (es)
DO (1) DOP2009000284A (es)
EA (1) EA018922B1 (es)
IL (1) IL202730A0 (es)
MA (1) MA31506B1 (es)
MX (1) MX2009013977A (es)
NZ (1) NZ581990A (es)
PE (1) PE20090694A1 (es)
TW (1) TW200916472A (es)
UY (1) UY31169A1 (es)
WO (1) WO2008156869A2 (es)
ZA (1) ZA200908883B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1910384T3 (da) * 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
WO2007041643A1 (en) * 2005-10-03 2007-04-12 University Of Tennessee Research Foundation Dietary calcium for reducing the production of reactive oxygen species
TW200918542A (en) 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
BRPI0814441A2 (pt) * 2007-07-19 2015-07-14 Schering Corp Compostos de amida heterocíclica como inibidores de proteína cinase
US20110009381A1 (en) * 2007-11-08 2011-01-13 Sirtis Pharmaceuticals, Inc. Solubilized thiazolopyridines
AU2009243006B2 (en) * 2008-05-01 2013-03-21 Sirtris Pharmaceuticals, Inc. Quinolines and related analogs as sirtuin modulators
KR20110036602A (ko) * 2008-07-03 2011-04-07 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 벤즈이미다졸 및 관련 유사체
AU2009295948B2 (en) 2008-09-29 2013-12-05 GlaxoSmithKline, LLC Quinazolinone, quinolone and related analogs as sirtuin modulators
EP2367563A4 (en) 2008-12-08 2012-12-19 Univ Northwestern METHOD FOR MODULATING HSF-1
EP2376502B1 (en) * 2008-12-19 2015-06-17 GlaxoSmithKline LLC Thiazolopyridine sirtuin modulating compounds
EP2493888B1 (en) 2009-10-29 2016-04-06 GlaxoSmithKline LLC Bicyclic pyridines and analogs as sirtuin modulators
EP2550260A1 (en) * 2010-03-24 2013-01-30 Medical University Of South Carolina Compositions and methods for the treatment of degenerative diseases
CN102985553B (zh) * 2010-04-15 2015-11-25 西特里斯药业公司 沉默调节蛋白活化剂和活化测定
CA2798218A1 (en) * 2010-05-03 2011-11-10 Curna, Inc. Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
EP2423214A1 (en) 2010-08-13 2012-02-29 Solvay SA Light emitting materials for Electronics
TW201223956A (en) 2010-08-13 2012-06-16 Solvay Light emitting materials for electronics
KR20120047341A (ko) * 2010-10-21 2012-05-14 경상대학교산학협력단 니코틴아미드를 유효성분으로 포함하는 알킬화 약물-유도성 신경퇴행의 예방 또는 치료용 조성물
US20130338178A1 (en) 2011-02-02 2013-12-19 The Trustees Of Princeton University Sirtuin modulators as inhibitors of cytomegalovirus
KR101329524B1 (ko) 2011-05-23 2013-11-13 연세대학교 산학협력단 미분화 전능성 줄기세포의 선택적 세포사멸 방법
CN108261547A (zh) 2011-07-15 2018-07-10 纽斯尔特科学公司 用于调节代谢途径的组合物和方法
CN104010651A (zh) 2011-09-07 2014-08-27 康奈尔大学 通过靶向Sirt5治疗癌症的方法
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
US9943517B2 (en) 2012-11-13 2018-04-17 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
JP6550370B2 (ja) 2013-03-15 2019-07-24 ニューサート サイエンシーズ， インコーポレイテッド 脂質レベルを低下させるロイシンおよびニコチン酸
EP3110507B1 (en) 2014-02-27 2020-11-18 NuSirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
WO2015143654A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
EP3149016A1 (en) 2014-06-02 2017-04-05 Glaxosmithkline Intellectual Property (No. 2) Limited Preparation and use of crystalline beta-d-nicotinamide riboside
RU2016149767A (ru) 2014-06-06 2018-07-16 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Аналоги никотинамидрибозида и фармацевтические композиции и их применение
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
CN107496410A (zh) * 2017-09-21 2017-12-22 上海华堇生物技术有限责任公司 洋槐黄素的药物用途
JP2021501198A (ja) * 2017-10-27 2021-01-14 トランスフュージョン ヘルス，リミティド ライアビリティ カンパニー フルオレンの誘導体を用いて造血幹細胞を増殖する組成物および方法
PE20210397A1 (es) 2018-02-20 2021-03-02 Incyte Corp Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cancer
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
EP4010338A1 (en) 2019-08-06 2022-06-15 Incyte Corporation Solid forms of an hpk1 inhibitor
WO2024005905A2 (en) * 2022-04-29 2024-01-04 The Regents Of The University Of Michigan Small molecule sirtuin inhibitors and uses thereof

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164603A (en) 1965-01-05 xnhcox
DE1108698B (de) 1959-09-03 1961-06-15 Hoechst Ag Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen
FR1439129A (fr) 1965-04-02 1966-05-20 Chimetron Nouveaux sulfonylbenzimidazoles
FR1476529A (fr) 1965-04-24 1967-04-14 Chimetron Sarl Nouveaux dérivés benzimidazole-sulfoniques et sulfamides correspondants
FR1450625A (fr) 1965-06-18 1966-06-24 Chimetron Sarl Sulfonamidothiazolyl-2 benzimidazoles
US3503929A (en) 1965-10-21 1970-03-31 Minnesota Mining & Mfg Polyimidazoquinazolines and polyamidobenzimidazoles
US3517007A (en) 1968-04-05 1970-06-23 American Home Prod 5 - acetamido - 4 - pyrimidinecarboxamides,5 - acetamido - 4 - pyrimidinecarboxylic acid hydrazides and related compounds
US3928228A (en) 1969-04-28 1975-12-23 Sterling Drug Inc 4,4{40 -Stilbenebis-pyridooxazoles and related optical brighteners and polymeric compositions brightened thereby
US3712888A (en) 1970-12-14 1973-01-23 American Cyanamid Co Bis-pyridoxazole-stilbene derivatives for optical brightening
CA1006165A (en) 1971-04-06 1977-03-01 Eastman Kodak Company Ballasted color photographic couplers
AR208500A1 (es) 1972-06-14 1977-02-15 Merck & Co Inc Procedimiento para la preparacion de derivados de oxazolo(4,5-b)-piridinas
US4038396A (en) 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
PL96241B1 (pl) 1975-06-30 1977-12-31 Sposob wytwarzania 2-/2-podstawionych-4-tiazolilo/-benzimidazoli
JPS6040016B2 (ja) 1977-08-31 1985-09-09 コニカ株式会社 マゼンタ色素画像の形成方法
US4471040A (en) 1980-09-10 1984-09-11 Canon Kabushiki Kaisha Electrophotographic disazo photosensitive member
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4939133A (en) 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
DE3807084A1 (de) 1988-03-04 1989-09-14 Knoll Ag Neue benzimidazo(1,2-c)chinazoline, ihre herstellung und verwendung
JPH04190232A (ja) 1990-11-26 1992-07-08 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JPH04191736A (ja) 1990-11-27 1992-07-10 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
JPH06247969A (ja) 1992-12-28 1994-09-06 Takeda Chem Ind Ltd 縮合複素環化合物及びそれを含む農園芸用殺虫剤
ES2172585T3 (es) 1994-05-31 2002-10-01 Mitsui Chemicals Inc Derivado de benzoimidazol.
US5821258A (en) * 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
AUPN449295A0 (en) 1995-07-28 1995-08-24 Inner And Eastern Health Care Network, The Radioprotectors
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5808087A (en) 1995-11-29 1998-09-15 Mitsui Chemicals, Inc. Sulfonium salts of pyrrolylbenzimidazoles
JP2002509858A (ja) 1997-12-31 2002-04-02 ルトガーズ，ザ ステイト ユニバーシティ オブ ニュージャージー 複素環式トポイソメラーゼ毒化合物
CA2326522A1 (en) * 1998-03-31 1999-10-14 Shionogi & Co., Ltd. Pyrrolo[1,2-a]pyrazine spla2 inhibitor
PL356984A1 (en) 1998-08-20 2004-07-12 Agouron Pharmaceuticals, Inc. Non-peptide gnrh agents, methods and intermediates for their preparation
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
EP1177188B1 (en) 1999-05-12 2005-10-12 Ortho-McNeil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
GB2351081A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
EP1194425B1 (de) 1999-06-23 2005-08-10 Aventis Pharma Deutschland GmbH Substituierte benzimidazole
AU7314200A (en) 1999-09-17 2001-04-24 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
EP1284260A4 (en) 2000-05-22 2004-03-31 Takeda Chemical Industries Ltd TYROSINE PHOSPHATASE INHIBITORS
MXPA02010763A (es) 2000-06-14 2003-03-10 Warner Lambert Co Heterociclicos biciclos-6,5 fusionados.
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
JP2002161084A (ja) 2000-11-28 2002-06-04 Sumitomo Pharmaceut Co Ltd 複素環誘導体
US20040010033A1 (en) 2001-02-20 2004-01-15 Pfizer Inc. Non-peptide GnRH agents, methods and intermediates for their preparation
WO2002066454A1 (en) 2001-02-21 2002-08-29 Sankyo Company, Limited Chromene derivatives
HUP0400323A2 (hu) 2001-03-28 2005-11-28 Bristol-Myers Squibb Company Tirozin-kináz inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
AU2002312371A1 (en) 2001-06-13 2002-12-23 Roland W. Burli Aryl-benzimidazole compounds having antiinfective activity
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
US8354397B2 (en) 2001-07-27 2013-01-15 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
WO2004043335A2 (en) 2001-09-13 2004-05-27 Genesoft, Inc. Methods of treating infection by drug resistant bacteria
US6897208B2 (en) 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
WO2003045929A1 (fr) 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Derive bicyclique, procede de production de ce derive et utilisation correspondante
US7163952B2 (en) 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
CN102151273B (zh) 2002-02-05 2015-11-25 安斯泰来制药有限公司 2,4,6-三氨基-1,3,5-三嗪衍生物
RU2004126671A (ru) 2002-02-06 2005-04-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероарилсоединения, полезные в качестве ингибиторов gsk-3
GB0205256D0 (en) 2002-03-06 2002-04-17 Oxford Glycosciences Uk Ltd Novel compounds
ATE432261T1 (de) 2002-03-18 2009-06-15 Merck Frosst Canada Ltd Pde4-inhibitoren mit heterobrückensubstituiertem 8-arylchinolin
EP1487843A4 (en) 2002-03-20 2010-03-10 Metabolex Inc SUBSTITUTED PHENYLACETIC ACIDS
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
JP4239463B2 (ja) 2002-04-09 2009-03-18 大正製薬株式会社 ３−トリフルオロメチルアニリド誘導体
JP4224979B2 (ja) 2002-04-09 2009-02-18 大正製薬株式会社 インターロイキン１２抑制剤
AU2003223631B2 (en) 2002-04-18 2006-07-20 Schering Corporation 1-(4-Piperidinyl) benzimidazolones as histamine H3 antagonists
JP2003313176A (ja) 2002-04-24 2003-11-06 Sankyo Co Ltd アミノアゾール誘導体
EP1510207A4 (en) 2002-06-05 2008-12-31 Inst Med Molecular Design Inc THERAPEUTIC MEDICAMENT AGAINST DIABETES
MXPA05000053A (es) 2002-07-12 2005-04-08 Aventis Pharma Gmbh Benzoilureas heterociclicamente sustituidas, metodo para su produccion y su uso como medicamentos.
DK1542997T3 (da) 2002-07-24 2012-06-25 Dermira Canada Inc Pyrazolylbenzothiazolderivater og deres anvendelse som terapeutiske midler
SE0202429D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
JP2004075614A (ja) 2002-08-20 2004-03-11 Sankyo Co Ltd クロメン誘導体を含有する医薬
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
US20040171073A1 (en) 2002-10-08 2004-09-02 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
BR0315158A (pt) 2002-10-09 2005-08-16 Pfizer Prod Inc Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
US8252520B2 (en) 2002-10-11 2012-08-28 Taivex Therapeutics Corporation Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases
EP1562931A2 (en) 2002-10-25 2005-08-17 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
WO2004041277A1 (en) 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
AU2003302497A1 (en) 2002-11-27 2004-06-23 Ph. D. Edward M. Eddy Glyceraldehyde 3-phosphate dehydrogenase-s(gapds), a glycolytic enzyme expressed only in male germ cells,is a target for male contraception
DE10300398A1 (de) 2003-01-09 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten 2-Phenylbenzimidazolen als Arzneimittel
EP1590339A4 (en) 2003-01-28 2007-07-25 Smithkline Beecham Corp CHEMICAL COMPOUNDS
CA2515215A1 (en) 2003-02-10 2004-08-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
MXPA05009063A (es) 2003-02-26 2005-12-12 Sugen Inc Compuestos de aminoheteroarilo como inhibidores de proteina cinasa.
BRPI0408251A (pt) 2003-03-11 2006-03-01 Pfizer Prod Inc compostos de pirazina como inibidores do fator de crescimento transformante (tgf)
WO2004084813A2 (en) 2003-03-21 2004-10-07 Smithkline Beecham Corporation Chemical compounds
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB2405793A (en) 2003-09-12 2005-03-16 4 Aza Bioscience Nv Pteridine derivatives for treating TNF-alpha related disorders
CA2534549A1 (en) 2003-09-12 2005-03-24 4 Aza Bioscience Nv Pteridine derivatives for the treatment of septic shock and tnf-.alpha.-related diseases.
CA2539314A1 (en) 2003-09-19 2005-03-31 F. Hoffmann-La Roche Ag Thiazolopyridine derivatives as adenosine receptor ligands
JP4795634B2 (ja) 2003-10-31 2011-10-19 出光興産株式会社 有機薄膜トランジスタ
JP2005162855A (ja) 2003-12-02 2005-06-23 Konica Minolta Holdings Inc 着色組成物、インクジェット記録用インク、カラートナー、光記録媒体、感熱転写記録材料用インクシート、カラーフィルター、及び該インクジェット記録用インクを用いたインクジェット記録方法
WO2005077939A1 (en) 2004-02-11 2005-08-25 Basilea Pharmaceutica Ag Substituted benzimidazoles and their use for inducing apoptosis
WO2005100342A1 (en) 2004-03-26 2005-10-27 Vertex Pharmaceuticals, Incorporated Pyridine inhibitors of erk2 and uses thereof
DE102004021716A1 (de) 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
BR122018075478B8 (pt) 2004-06-24 2023-10-31 Vertex Pharma moduladores de transportadores de cassete de ligação de atp
KR20070049655A (ko) 2004-08-13 2007-05-11 제넨테크, 인크. Ａｔｐ-이용 효소 억제 활성을 나타내는2-아미도-티아졸-기재 화합물과 조성물 및 이들의 용도
DE102004039789A1 (de) * 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
WO2006050506A1 (en) 2004-11-03 2006-05-11 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
AU2005304393B2 (en) 2004-11-10 2012-09-27 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
JP4635633B2 (ja) 2005-02-04 2011-02-23 横浜ゴム株式会社 空気入りタイヤおよびその製造方法
AU2006218404A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
DK1910384T3 (da) 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7935957B2 (en) * 2005-08-12 2011-05-03 Semiconductor Energy Laboratory Co., Ltd. Memory device and a semiconductor device
JP4191736B2 (ja) 2006-01-11 2008-12-03 日本電信電話株式会社 電界通信システム
WO2008106692A1 (en) 2007-03-01 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Pim kinase inhibitors and methods of their use
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
TW200918542A (en) * 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
US20100168084A1 (en) * 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use

Also Published As

Publication number Publication date
JP2010530432A (ja) 2010-09-09
AR067107A1 (es) 2009-09-30
NZ581990A (en) 2012-07-27
PE20090694A1 (es) 2009-06-20
US20110152254A1 (en) 2011-06-23
TW200916472A (en) 2009-04-16
BRPI0813651A2 (pt) 2014-12-30
MX2009013977A (es) 2010-04-09
US20090105246A1 (en) 2009-04-23
US8268862B2 (en) 2012-09-18
JP5498940B2 (ja) 2014-05-21
US7893086B2 (en) 2011-02-22
AU2008266749C1 (en) 2012-11-01
AU2008266749B2 (en) 2012-03-15
MA31506B1 (fr) 2010-07-01
CN103833775A (zh) 2014-06-04
EA018922B1 (ru) 2013-11-29
CL2008001822A1 (es) 2009-03-13
CR11232A (es) 2010-05-24
IL202730A0 (en) 2010-06-30
CA2691733A1 (en) 2008-12-24
CN101801981A (zh) 2010-08-11
ZA200908883B (en) 2010-08-25
WO2008156869A2 (en) 2008-12-24
KR20100051048A (ko) 2010-05-14
WO2008156869A3 (en) 2009-05-14
EA201070035A1 (ru) 2010-06-30
UY31169A1 (es) 2009-01-30
EP2170905A2 (en) 2010-04-07
DOP2009000284A (es) 2010-02-28
AU2008266749A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
CO6251248A2 (es) Compuestos de tiazolopiridina como moduladores de sirtuina
AR120896A1 (es) COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
CO6170361A2 (es) Composiciones y metodos para modular receptores de c-kit y pdgfr
PE20091005A1 (es) N-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas
AR073369A1 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
CO6270320A2 (es) Derivados de piperidina utiles como antagonistas del receptor orexina
NO20064309L (no) Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer
AR041250A1 (es) Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa
BR112015010244A8 (pt) compostos de piridila substituída por alquil-amida úteis como moduladores de il-12, il-23 e/ou respostas de ifnalfa, sua composição farmacêutica e seu uso
AR114793A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
CO6261382A2 (es) Compuestos de imidazotiazol como moduladores de sirtuina
CO6231028A2 (es) Compuestos y composiciones como inhibidores de la proteina quinasa
TW200738685A (en) Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
AR077849A2 (es) Compuestos y composiciones como inhibidores de proteina quinasa
ATE432272T1 (de) Aminophenylderivate als neue inhibitoren von histondeacetylase
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
CO6220878A2 (es) Composicion herbicida que comprende un derivado de isoxazolina o una sal del mismo
EA201170384A1 (ru) Пиррольные соединения
AR056025A1 (es) Compuestos de imidazol sustituidos como inhibidores de ksp
NI200800247A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
EA201170099A1 (ru) Замещенные пиримидин-4-оновые производные
AR093077A1 (es) ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS
ATE434603T1 (de) Chinazolinderivate als antivirale mittel
EA201000619A1 (ru) Новые производные имидазола

Legal Events

Date Code Title Description
FC Application refused